Edition:
United States

Pacira Pharmaceuticals Inc (PCRX.OQ)

PCRX.OQ on NASDAQ Stock Exchange Global Select Market

34.55USD
16 Oct 2017
Change (% chg)

-- (--)
Prev Close
$34.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
161,372
52-wk High
$58.80
52-wk Low
$30.00

Chart for

About

Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product... (more)

Overall

Beta: 2.07
Market Cap(Mil.): $1,381.70
Shares Outstanding(Mil.): 40.34
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.52 16.83
EPS (TTM): -- -- --
ROI: -- 14.97 10.92
ROE: -- 16.23 14.52

BRIEF-‍Point72 Asset Management LP reports a 5 pct passive stake in Pacira Pharmaceuticals ​

* ‍Point72 Asset Management LP reports a 5.0 pct passive stake in Pacira Pharmaceuticals Inc as of Aug 21 - SEC filing ​ Source text: (http://bit.ly/2io69IV) Further company coverage:

Aug 22 2017

BRIEF-Healthcor Management L.P.‍ reports a 6.2 pct passive stake in Pacira Pharmaceuticals

* Healthcor Management L.P.‍ reports a 6.2 pct passive stake in Pacira Pharmaceuticals, as of Aug 3 - SEC filing ​ Source text for Eikon: (http://bit.ly/2fEM3Jn) Further company coverage:

Aug 14 2017

BRIEF-Pacira Pharma says data on Exparel published in medical journal

* Pacira announces publication of phase 4 study of exparel in patients undergoing total knee replacement in the journal of arthroplasty Source text for Eikon: Further company coverage:

Jul 26 2017

BRIEF-Pacira announces topline phase 3 results for Exparel

* Pacira announces topline phase 3 results for Exparel as a single-dose nerve block

Jul 25 2017

BRIEF-Pacira Pharma says President James Scibetta has resigned

* Pacira pharmaceuticals -james scibetta resigning as president to become ceo of an undisclosed private early-stage oncology company

May 23 2017

BRIEF-Pacira Pharmaceuticals Inc reports Q1 GAAP loss per share $0.52

* Pacira pharmaceuticals, inc. Reports first quarter 2017 financial results

May 04 2017

Competitors

Earnings vs. Estimates